Profund Advisors LLC Purchases 104,927 Shares of Ocular Therapeutix, Inc. $OCUL

Profund Advisors LLC lifted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 316.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 138,128 shares of the biopharmaceutical company’s stock after purchasing an additional 104,927 shares during the quarter. Profund Advisors LLC owned about 0.06% of Ocular Therapeutix worth $1,059,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its holdings in Ocular Therapeutix by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 40,071 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 5,223 shares in the last quarter. Deltec Asset Management LLC increased its stake in Ocular Therapeutix by 6.0% in the 3rd quarter. Deltec Asset Management LLC now owns 2,623,597 shares of the biopharmaceutical company’s stock worth $20,123,000 after acquiring an additional 147,400 shares during the last quarter. Sterling Capital Management LLC increased its stake in Ocular Therapeutix by 401.7% in the 3rd quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 5,294 shares during the last quarter. Root Financial Partners LLC purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter worth approximately $66,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Ocular Therapeutix during the 2nd quarter worth approximately $401,000. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Trading Up 1.3%

OCUL opened at $6.82 on Wednesday. The stock has a 50-day moving average of $8.65 and a 200 day moving average of $9.09. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14. Ocular Therapeutix, Inc. has a 12 month low of $6.00 and a 12 month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) earnings per share. On average, sell-side analysts expect that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the completion of the transaction, the insider owned 254,388 shares in the company, valued at approximately $1,793,435.40. The trade was a 3.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Anderman sold 11,984 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $7.29, for a total value of $87,363.36. Following the transaction, the insider directly owned 140,484 shares in the company, valued at approximately $1,024,128.36. This represents a 7.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 62,720 shares of company stock worth $556,247 in the last 90 days. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on OCUL. HC Wainwright reiterated a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, October 20th. Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research report on Monday, October 19th. UBS Group began coverage on shares of Ocular Therapeutix in a research report on Sunday, October 11th. They issued a “buy” rating and a $14.00 price target on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Finally, Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications.

Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis.